Cargando…

Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study

This study aimed to investigate the influence of sex, age, and quadrivalent vaccination history on adverse reactions (ARs) to influenza vaccines and the relationship between the occurrence of ARs and the risk of influenza infection. Study participants were employees of three hospitals in the Hyogo P...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumabe, Ayako, Kenzaka, Tsuneaki, Yahata, Shinsuke, Goda, Ken, Okayama, Masanobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610483/
https://www.ncbi.nlm.nih.gov/pubmed/36298529
http://dx.doi.org/10.3390/vaccines10101664
_version_ 1784819280643096576
author Kumabe, Ayako
Kenzaka, Tsuneaki
Yahata, Shinsuke
Goda, Ken
Okayama, Masanobu
author_facet Kumabe, Ayako
Kenzaka, Tsuneaki
Yahata, Shinsuke
Goda, Ken
Okayama, Masanobu
author_sort Kumabe, Ayako
collection PubMed
description This study aimed to investigate the influence of sex, age, and quadrivalent vaccination history on adverse reactions (ARs) to influenza vaccines and the relationship between the occurrence of ARs and the risk of influenza infection. Study participants were employees of three hospitals in the Hyogo Prefecture, Japan, who received the influenza vaccine in 2019. Data were collected using questionnaires. The main factors were age, sex, and history of influenza vaccination as a control. The primary outcomes were the incidence of local and systemic ARs attributable to the vaccine and positive influenza cases among the participants during the influenza season. Logistic regression was used to calculate the odds ratio (OR) and 95% confidence interval (CI). Among the 1493 participants, 80% experienced either local or systemic ARs. ARs were less common among men than among women (OR: 0.28, 95% CI: 0.21–0.37) and less common among those aged ≥60 years (OR: 0.48, 95% CI: 0.26–0.89). ARs were significantly more likely to occur in those with a history of influenza vaccination (OR: 1.96, 95% CI: 1.15–3.33). Those who had ARs, notably localized ones, were significantly more likely to incur influenza infection. Individuals who report ARs to influenza vaccination should strictly adopt non-pharmaceutical preventive measures in the hospital, community settings, and at home.
format Online
Article
Text
id pubmed-9610483
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96104832022-10-28 Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study Kumabe, Ayako Kenzaka, Tsuneaki Yahata, Shinsuke Goda, Ken Okayama, Masanobu Vaccines (Basel) Article This study aimed to investigate the influence of sex, age, and quadrivalent vaccination history on adverse reactions (ARs) to influenza vaccines and the relationship between the occurrence of ARs and the risk of influenza infection. Study participants were employees of three hospitals in the Hyogo Prefecture, Japan, who received the influenza vaccine in 2019. Data were collected using questionnaires. The main factors were age, sex, and history of influenza vaccination as a control. The primary outcomes were the incidence of local and systemic ARs attributable to the vaccine and positive influenza cases among the participants during the influenza season. Logistic regression was used to calculate the odds ratio (OR) and 95% confidence interval (CI). Among the 1493 participants, 80% experienced either local or systemic ARs. ARs were less common among men than among women (OR: 0.28, 95% CI: 0.21–0.37) and less common among those aged ≥60 years (OR: 0.48, 95% CI: 0.26–0.89). ARs were significantly more likely to occur in those with a history of influenza vaccination (OR: 1.96, 95% CI: 1.15–3.33). Those who had ARs, notably localized ones, were significantly more likely to incur influenza infection. Individuals who report ARs to influenza vaccination should strictly adopt non-pharmaceutical preventive measures in the hospital, community settings, and at home. MDPI 2022-10-06 /pmc/articles/PMC9610483/ /pubmed/36298529 http://dx.doi.org/10.3390/vaccines10101664 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kumabe, Ayako
Kenzaka, Tsuneaki
Yahata, Shinsuke
Goda, Ken
Okayama, Masanobu
Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study
title Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study
title_full Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study
title_fullStr Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study
title_full_unstemmed Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study
title_short Evaluation of Adverse Reactions to Influenza Vaccination: A Prospective Cohort Study
title_sort evaluation of adverse reactions to influenza vaccination: a prospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9610483/
https://www.ncbi.nlm.nih.gov/pubmed/36298529
http://dx.doi.org/10.3390/vaccines10101664
work_keys_str_mv AT kumabeayako evaluationofadversereactionstoinfluenzavaccinationaprospectivecohortstudy
AT kenzakatsuneaki evaluationofadversereactionstoinfluenzavaccinationaprospectivecohortstudy
AT yahatashinsuke evaluationofadversereactionstoinfluenzavaccinationaprospectivecohortstudy
AT godaken evaluationofadversereactionstoinfluenzavaccinationaprospectivecohortstudy
AT okayamamasanobu evaluationofadversereactionstoinfluenzavaccinationaprospectivecohortstudy